BRPI0900896B8 - cepa de bcg pasteur auxotrófico recombinante - Google Patents

cepa de bcg pasteur auxotrófico recombinante

Info

Publication number
BRPI0900896B8
BRPI0900896B8 BRPI0900896A BRPI0900896A BRPI0900896B8 BR PI0900896 B8 BRPI0900896 B8 BR PI0900896B8 BR PI0900896 A BRPI0900896 A BR PI0900896A BR PI0900896 A BRPI0900896 A BR PI0900896A BR PI0900896 B8 BRPI0900896 B8 BR PI0900896B8
Authority
BR
Brazil
Prior art keywords
delta
strain
recombinant
pasteur
hsp60
Prior art date
Application number
BRPI0900896A
Other languages
English (en)
Inventor
j g simpson Andrew
Mcintosh Douglas
Rodrigues Garcia Armôa Geraldo
Tendler Miriam
Magno Vilar Mônica
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to BRPI0900896A priority Critical patent/BRPI0900896B8/pt
Priority to AP2011005916A priority patent/AP3794A/en
Priority to CN2010800204174A priority patent/CN102439155A/zh
Priority to AU2010223786A priority patent/AU2010223786B2/en
Priority to ES10750256.9T priority patent/ES2595372T3/es
Priority to NZ595662A priority patent/NZ595662A/xx
Priority to EP10750256.9A priority patent/EP2407545B1/en
Priority to PCT/BR2010/000065 priority patent/WO2010102363A1/pt
Priority to JP2011553235A priority patent/JP2012519496A/ja
Priority to US13/255,734 priority patent/US20120093774A1/en
Publication of BRPI0900896A2 publication Critical patent/BRPI0900896A2/pt
Publication of BRPI0900896B1 publication Critical patent/BRPI0900896B1/pt
Publication of BRPI0900896B8 publication Critical patent/BRPI0900896B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/43559—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from trematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

cepa de bcg pasteur auxotrófico recombinante e seu uso no controle de infecções humanas causadas por parasitas. a presente invenção se refere a uma cepa vacinal de mycobacterium bovis bcg recombinante expressando o antígeno sm14 de schistosoma mansoni (bcgr pasteur (delta)leud/p(delta)k410-hsp60*-sm14). a cepa vacinal da presente invenção é empregada para o controle de infecções causadas por parasitas, especialmente schistosoma mansoni. a cepa vacinal é uma cepa auxotrófica para o aminoácido leucina derivada da subcepa bcg pasteur complementada para leucina após transformação genética com a construção p(delta)k410-hsp60*-sm14. a eficácia da cepa bcgr pasteur (delta)leud/p(delta)k410-hsp60*-sm14 para o controle da infecção com schistosorna mansoni com base na expressão do antígeno sm14 recombinante in vivo é demonstrada na presente invenção.
BRPI0900896A 2009-03-11 2009-03-11 cepa de bcg pasteur auxotrófico recombinante BRPI0900896B8 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0900896A BRPI0900896B8 (pt) 2009-03-11 2009-03-11 cepa de bcg pasteur auxotrófico recombinante
AP2011005916A AP3794A (en) 2009-03-11 2010-03-10 Auxotrophic recombinant BCG strain pasteur and usethereof in the control of human infections caused by parasites.
CN2010800204174A CN102439155A (zh) 2009-03-11 2010-03-10 营养缺陷型重组体巴斯德bcg菌株及其在抗寄生虫导致的人体感染中的应用
AU2010223786A AU2010223786B2 (en) 2009-03-11 2010-03-10 Auxotrophic, recombinant BCG strain Pasteur and use thereof for combating human infections caused by parasites
ES10750256.9T ES2595372T3 (es) 2009-03-11 2010-03-10 Cepa Pasteur de BCG auxótrofa y recombinante y su uso para combatir infecciones humanas causadas por parásitos
NZ595662A NZ595662A (en) 2009-03-11 2010-03-10 Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
EP10750256.9A EP2407545B1 (en) 2009-03-11 2010-03-10 Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
PCT/BR2010/000065 WO2010102363A1 (pt) 2009-03-11 2010-03-10 Cepa de bcg pasteur auxotrófico recombinante e seu uso no controle de infecções humanas causadas por parasitas
JP2011553235A JP2012519496A (ja) 2009-03-11 2010-03-10 組換え型栄養要求性ｂｃｇパスツール株及び、寄生虫によって引き起こされるヒトの感染症を制御するための同株の使用
US13/255,734 US20120093774A1 (en) 2009-03-11 2010-03-10 Auxotrophic recombinant bcg strain pasteur and use thereof in the control of human infections caused by parasites

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0900896A BRPI0900896B8 (pt) 2009-03-11 2009-03-11 cepa de bcg pasteur auxotrófico recombinante

Publications (3)

Publication Number Publication Date
BRPI0900896A2 BRPI0900896A2 (pt) 2010-11-16
BRPI0900896B1 BRPI0900896B1 (pt) 2020-12-08
BRPI0900896B8 true BRPI0900896B8 (pt) 2021-05-25

Family

ID=42727722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0900896A BRPI0900896B8 (pt) 2009-03-11 2009-03-11 cepa de bcg pasteur auxotrófico recombinante

Country Status (10)

Country Link
US (1) US20120093774A1 (pt)
EP (1) EP2407545B1 (pt)
JP (1) JP2012519496A (pt)
CN (1) CN102439155A (pt)
AP (1) AP3794A (pt)
AU (1) AU2010223786B2 (pt)
BR (1) BRPI0900896B8 (pt)
ES (1) ES2595372T3 (pt)
NZ (1) NZ595662A (pt)
WO (1) WO2010102363A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103203028A (zh) * 2012-12-03 2013-07-17 西南大学 一种提高抗肝片吸虫病dna疫苗免疫保护率的疫苗组合及制备方法
BR102018003245A2 (pt) * 2018-02-20 2019-09-10 Fundação Oswaldo Cruz oligonucleotídeo, conjunto de oligonucleotídeos, método para detecção simultânea de neisseria meningitidis, streptococcus pneumoniae e haemophilus influenzae, e, kit.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0303266B8 (pt) * 2003-01-31 2021-05-25 Fundacao Oswaldo Cruz proteína recombinante sm14, composição imunogênica, e,kit de diagnóstico.

Also Published As

Publication number Publication date
NZ595662A (en) 2013-09-27
WO2010102363A1 (pt) 2010-09-16
ES2595372T3 (es) 2016-12-29
AU2010223786B2 (en) 2016-07-14
AP2011005916A0 (en) 2011-10-31
EP2407545A1 (en) 2012-01-18
CN102439155A (zh) 2012-05-02
EP2407545A4 (en) 2013-06-19
AU2010223786A1 (en) 2011-11-03
JP2012519496A (ja) 2012-08-30
US20120093774A1 (en) 2012-04-19
AP3794A (en) 2016-08-31
BRPI0900896B1 (pt) 2020-12-08
BRPI0900896A2 (pt) 2010-11-16
EP2407545B1 (en) 2016-07-06
WO2010102363A8 (pt) 2011-10-06

Similar Documents

Publication Publication Date Title
MX2011008791A (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
WO2010033274A3 (en) Nanoemulsion adjuvants
MX2011011186A (es) Una vacuna antituberculosis tb para evitar la reactivacion.
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BR112012005349A2 (pt) composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
WO2014009586A8 (es) Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente
AU2012277893A8 (en) Canine coronavirus vaccine
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
WO2012036391A3 (ko) 돼지 써코바이러스２(ｐｃｖ２) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주
BRPI0900896B8 (pt) cepa de bcg pasteur auxotrófico recombinante
BR112015023738A2 (pt) vacinas de nucleoproteina influenza
CO6700818A2 (es) Vectores de parapoxvirus
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
ECSP088907A (es) Vacuna en contra de organismos similares a rickettsia
WO2012073257A3 (en) Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine
AR088176A1 (es) Secuencias de aminoacidos para el control de patogenos

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed